We have located links that may give you full text access.
Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis.
Annals of Surgical Oncology 2013 Februrary
BACKGROUND: The most reliable prognostic factor to date is tumor, node, metastasis stage. However, prognostic significance of tumor-infiltrating lymphocytes (TILs) in curatively resected stage IV colon cancer with isolated liver or lung lesion has not been clarified. The aim of this study was to assess and compare the prognostic role of TILs in curatively resected stage IV colon cancers.
METHODS: Immunohistochemistry was used to assess the densities of CD8(+), CD45RO(+), and FOXP3(+) according to tumor sites (primary tumor, liver, and lung) from 79 stage IV colon cancers. These were evaluated for association with histopathologic features and patients' overall survival (OS).
RESULTS: Higher density of CD45RO(+) at primary and metastatic sites was associated with better patient outcomes (P = 0.009 and 0.027, respectively). The estimated 3-year OS rates for high-density CD45RO(+) at metastatic and primary sites was 82.6 and 62.4 %, respectively, compared to 60.8 and 27.1 % in low-density CD45RO(+). In multivariate analysis, CD45RO(+) at the colon primary site (P = 0.007; relative risk 0.108; 95 % confidence interval 0.021-0.546) was the strongest prognostic factor.
CONCLUSIONS: High density of CD45RO(+) TILs showed independent prognostic significance for OS. This result may help to improve the prognostication of curatively resected stage IV colon cancer.
METHODS: Immunohistochemistry was used to assess the densities of CD8(+), CD45RO(+), and FOXP3(+) according to tumor sites (primary tumor, liver, and lung) from 79 stage IV colon cancers. These were evaluated for association with histopathologic features and patients' overall survival (OS).
RESULTS: Higher density of CD45RO(+) at primary and metastatic sites was associated with better patient outcomes (P = 0.009 and 0.027, respectively). The estimated 3-year OS rates for high-density CD45RO(+) at metastatic and primary sites was 82.6 and 62.4 %, respectively, compared to 60.8 and 27.1 % in low-density CD45RO(+). In multivariate analysis, CD45RO(+) at the colon primary site (P = 0.007; relative risk 0.108; 95 % confidence interval 0.021-0.546) was the strongest prognostic factor.
CONCLUSIONS: High density of CD45RO(+) TILs showed independent prognostic significance for OS. This result may help to improve the prognostication of curatively resected stage IV colon cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app